Hospital
MH Angel Medical Center, LLLP
MH Angel Medical Center, LLLP was paid $7.05M by Medicaid between Feb 2019 and Dec 2024, across 81 billing codes. Its largest line is 99283, emergency room visit (moderate) — 28% of everything it billed.
33Billing provider infoMH ANGEL MEDICAL CENTER, LLLP
FRANKLIN, NC 28734
FRANKLIN, NC 28734
33aNPI1023593746assigned 09/27/2018
33bProvider typeCritical Access Hospital
28Total paid$7.05M
24GClaims106,863
24DCodes billed81
24AFirst – last monthFeb 2019 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in North Carolina
Rank by total paid#3 of 25
Median peer was paid$1.32M
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 17,474 | $1.04M | |
| 2020 | 21,781 | $1.39M | |
| 2021 | 19,806 | $1.22M | |
| 2022 | 16,190 | $928K | |
| 2023 | 18,406 | $1.22M | |
| 2024incomplete | 13,206 | $1.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 28% | 11,300 | 9,954 | $2.00M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 6,998 | 5,888 | $1.66M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 12% | 1,130 | 995 | $880K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.0% | 1,744 | 1,501 | $565K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 860 | 740 | $233K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 2,397 | 2,178 | $194K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 3,383 | 2,804 | $148K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 2,899 | 2,657 | $121K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.4% | 1,589 | 1,473 | $102K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 2,882 | 2,370 | $94K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 1,799 | 1,336 | $94K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 2,187 | 1,905 | $92K |
69 more codes
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.2% | 3,021 | $86K |
| 80053 | Comprehensive metabolic panel | 1.1% | 9,887 | $75K |
| 85027 | <1% | 11,819 | $67K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,366 | $65K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,379 | $58K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 791 | $55K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 827 | $53K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,590 | $39K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,025 | $27K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 101 | $22K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 31 | $21K |
| 96376 | <1% | 292 | $16K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 201 | $16K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 735 | $14K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 587 | $14K |
| 80061 | Lipid panel | <1% | 1,337 | $14K |
| 81001 | <1% | 4,710 | $13K | |
| 87634 | <1% | 253 | $13K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 795 | $13K |
| 80306 | <1% | 579 | $12K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,182 | $12K |
| 83690 | <1% | 2,145 | $12K | |
| 84484 | <1% | 1,917 | $11K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 274 | $11K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 335 | $10K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 555 | $9K |
| 83880 | <1% | 537 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,450 | $9K |
| 83605 | <1% | 1,030 | $7K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,109 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,003 | $7K |
| 71250 | <1% | 28 | $6K | |
| 81025 | <1% | 918 | $6K | |
| 83735 | <1% | 1,313 | $6K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 105 | $5K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $5K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 14 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 166 | $4K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 113 | $4K |
| 87040 | <1% | 543 | $4K | |
| 85610 | <1% | 1,439 | $4K | |
| 74018 | <1% | 57 | $4K | |
| 84439 | <1% | 286 | $2K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 134 | $2K |
| 87077 | <1% | 279 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 14 | $2K |
| 87186 | <1% | 251 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 197 | $2K |
| 73110 | <1% | 19 | $2K | |
| 84703 | <1% | 185 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 232 | $920.31 |
| 73610 | <1% | 12 | $832.06 | |
| 85730 | <1% | 281 | $781.48 | |
| 73630 | <1% | 12 | $733.34 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 27 | $417.32 |
| 82607 | <1% | 29 | $377.80 | |
| 86140 | <1% | 84 | $305.49 | |
| J3490 | Unclassified drugs | <1% | 636 | $289.28 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 17 | $288.81 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 17 | $288.81 |
| 85652 | <1% | 101 | $234.15 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 26 | $214.78 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 12 | $193.10 |
| 85379 | <1% | 13 | $67.16 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 25 | $59.28 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 38 | $54.34 |
| 87210 | <1% | 13 | $49.90 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 165 | $0.00 |
| 82077 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKENDALL, CLINT (CEO)